Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes – Yahoo Finance

– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 –
CAMBRIDGE, Mass., December 21, 2022–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase (KHK) for the treatment of Type 2 diabetes mellitus (T2DM). Pending regulatory authority and ethic committee approvals, the Company plans to begin enrollment in a Phase 1/2 study in healthy overweight to obese volunteers and obese patients with T2DM in early 2023, and expects to report initial human data in late 2023.
"We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic to address the unmet medical need in Type 2 diabetes mellitus and potentially other metabolic disorders," said Neil Wallace, Program Leader for the ALN-KHK program at Alnylam. "Increased dietary fructose consumption, largely resulting from use of high-fructose corn syrup as a sweetener, is believed to contribute to the growing pandemic of obesity. Obesity is a significant risk factor for both T2DM and fatty liver disease. Fructose itself predisposes to fatty liver disease and thus, in the context of T2DM, aggravates insulin resistance. We believe targeting ketohexokinase, also known as fructokinase, the first enzyme in the pathway of fructose metabolism, is a novel therapeutic approach to reduce fatty acid synthesis and insulin resistance, with the potential to improve overall glycemic control in individuals with T2DM."
ALN-KHK is a wholly-owned asset in the Alnylam clinical development portfolio.
About ALN-KHK
ALN-KHK is an investigational, subcutaneously administered RNAi therapeutic targeting ketohexokinase for the treatment of Type 2 diabetes mellitus (T2DM). ALN-KHK utilizes Alnylam's Enhanced Stabilization Chemistry Plus (ESC+) GalNAc-conjugate technology, which enables subcutaneous dosing with increased selectivity and a wide therapeutic index. The safety and efficacy of ALN-KHK have not been evaluated by the FDA, EMA, Health Canada, or any other health authority.
About Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM) is a global disease affecting more than 6% of the world’s population. Its incidence and prevalence rates are believed to be increasing worldwide with estimates of more than 450 million affected. The prevalence of diabetes is expected to reach 55 million within the US by 2030. Management of T2DM is aimed at achieving a target hemoglobin A1c levels (a measure of blood sugar) of less than 7%. Typically diet and exercise are recommended with the aim of achieving weight loss; this is rarely successful. Despite a number of treatment options, many patients do not reach adequate blood sugar control. There is an unmet need for a treatment that can produce sufficient glycemic control while providing simpler dosing administration and longer dosing intervals that could improve treatment compliance, thereby reducing disease complications and overall mortality.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), AMVUTTRA^® (vutrisiran) and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P⁵x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations beliefs, goals, plans or prospects, including, without limitation, expectations regarding Alnylam’s aspiration to become a leading biotech company and the planned achievement of its "Alnylam P⁵x25" strategy, the potential for Alnylam to identify new potential drug development candidates and advance its research and development programs, Alnylam’s ability to obtain approval for new commercial products or additional indications for its existing products, and Alnylam’s projected commercial and financial performance, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic; the potential impact of the January 2022 leadership transition on Alnylam’s ability to attract and retain talent and to successfully execute on its "Alnylam P⁵x25" strategy; Alnylam's ability to discover and develop novel drug candidates and delivery approaches, including using Alnylam’s IKARIA and GEMINI platforms, and successfully demonstrate the efficacy and safety of its product candidates, including ALN-KHK; the pre-clinical and clinical results for its product candidates, including ALN-KHK; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, including ALN-KHK, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO or AMVUTTRA in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of a current government investigation and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
This press release discusses investigational RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. There is no guarantee that any investigational therapeutics will successfully complete clinical development or gain health authority approval.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221221005114/en/
Contacts
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
+1-617-682-4340
Josh Brodsky
(Investors)
+1-617-551-8276
Related Quotes
Shares of Chinese pharmaceutical companies plunged Tuesday morning on Chinese bourses, continuing a slide that began in the face of competition from Pfizer's COVID-19 drug Paxlovid earlier this month.
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.
It has been a rough year for biotech stocks. It doesn't make sense to write off the entire biotech sector, however. Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL) are growing revenue and net income, making the two mid-cap biotech stocks attractive long-term buys.
When does a high-deductible health plan make sense? Here's who can benefit the most from an HDHP.
In a post on Twitter, he also complained of being injected with unknown drugs. "See how the system works when you are not allowed to beat up a person, but your leadership ordered you to hurt them badly," the Twitter post said. Navalny said he had asked for a month and a half to see a doctor.
Britain will stop publishing the COVID-19 R number that measures how quickly the disease is spreading among the population, saying on Monday it was not needed anymore thanks to vaccines and drugs. The R number, or "reproduction number", has been a staple of coronavirus data bulletins in the last three years. An R number of 2, for example, means a person with COVID-19 will infect two other people.
Photo Illustration by Thomas Levinson/The Daily Beast/Getty2023 could be the year the world finally figures out how to live with COVID. Well, most of the world. Ironically, we’ll have the Omicron variant of the SARS-CoV-2 virus to thank for it.Successive waves of infections from Omicron and its subvariants, starting in late 2021, have produced so much natural immunity across the human population that most countries are now in a good position to weather new subvariants. “I see the United States a
An alphabet soup of respiratory illnesses has been spreading misery across the United States, once again pushing hospital staff to the brink. But Gena Oppenheim, an intensive care nurse in Santa Monica, California, was taking it all in stride last week as the bed count at Providence Saint John’s Health Center continued the ominous rise that had begun around Thanksgiving. Like countless other health care workers throughout the country, Oppenheim, 32, feels emotionally battered by the past three y
Mask-wearing Beijing and Shanghai commuters crowded subway trains on Monday as China's two biggest cities edged closer to living with COVID-19 even as frontline medical workers scrambled to cope with millions of new infections. After three years of harsh anti-coronavirus curbs, President Xi Jinping scrapped China's zero-COVID policy of lockdowns and relentless testing on Dec. 7 in the face of public protests and a widening outbreak.
Despite lucrative tax breaks for serving needy communities, many large systems focus growth on higher-income neighborhoods.
STORY: There were signs that mainland China’s biggest cities were edging closer to living with COVID-19 on Monday with packed morning subway trains in Beijing and Shanghai. People mostly stayed home in the weeks after China scrapped its ruthless zero-COVID restrictions as they tried avoid the disease or dealt with an infection.China is the last major country to move toward treating COVID as endemic.Now, the virus is infecting millions, left largely unchecked across the country while residents have returned to commuting to work.“I am prepared to live with the pandemic. After all, lockdowns are not a long term solution,” 25-year-old Lin Zixin told Reuters.Shanghai’s streets in particular – even with just a handful of cars on the road — were a sharp contrast to April and May.That’s when the city endured a strict and bitter lockdown… and hardly anyone went outside.China had reported no new COVID deaths for the six days through Sunday.However, health experts and residents worry that China’s statistics do not reflect the actual number of fatalities.The country has narrowed its definition for classifying deaths as COVID-related, counting only those involving COVID-caused pneumonia or respiratory failure.And the country’s health system has been under enormous strain.Health care staff have been asked to work while sick or retired medical workers being rehired to help, according to state media.Analysts say the economy, the second-biggest in the world, is expected to suffer further in the short-term after zero-COVID slowed China growth to its lowest rate in nearly half a century.
More than 80 children have been infected with measles in central Ohio as an outbreak in the state continues to spread rapidly among the unvaccinated population. The measles virus is primarily spreading around the city of Columbus and has infected at least 81 children so far, hospitalizing 29 of them, officials reported last week. Health…
A vaccine for Strep A is on the horizon after scientists discovered a crucial bacteria-fighting antibody in a recovered patient.
Chinese authorities are going door to door and paying people older than 60 to get vaccinated against COVID-19. “When people hear about such incidents, they may not be willing to take the vaccines,” said Li, who had been vaccinated before he caught COVID-19. A few days after his 10-day bout with the virus, Li is nursing a sore throat and cough.
After experiencing a dozen initial public stock offerings by companies in the region's life sciences industry in 2020 and 2021, this year no IPOs were completed by Philadelphia-area drug developers or medical device manufacturers because of the unfavorable climate on Wall Street. The down market, analysts said, drove investors away from biotech stocks to less expensive, and less risky, sectors of the economy — resulting in the lowest volume of life sciences IPOs in more than five years in 2022. One company, New Hope-based Orchestra BioMed Holdings, in July began the process of going public through a merger with a SPAC, or special purpose acquisition company, called Health Sciences Acquisition Corp 2.
Bitsy Cherry had been bracing for the question ever since most of the members of a board game group that had started meeting online during the pandemic began attending in-person meetings a few months ago. Like many of the dwindling group of Americans still taking precautions such as masking indoors and limiting face-to-face interactions, Cherry, who uses gender-neutral courtesy titles and pronouns, had been fielding nudges to return to pre-COVID routines from all corners. Doctors’ offices that h
Coughing is a common symptom of COVID-19, but sometimes it lingers even after the infection clears up. Here's how long it can last and how to get rid of it.
You might know or have experienced a few causes of workplace stress, but are you familiar with the most widely recognized ones? Stressors left unchecked may begin to show up as physical, mental and/or…
An increase in this particular biometric is a good thing. visualspace/E+ via Getty ImagesYour heart beats around 100,000 times every day. Heart rate is a key marker of cardiovascular activity and an important vital sign. But your pulse is not as steady as a precision clock – nor would you want it to be. As a cardiovascular physiologist, I measure heart rate in nearly every experiment my students and I perform. Sometimes we use an electrocardiogram, such as you’d see in a medical clinic, which us
As China grapples with its first-ever national Covid-19 wave, emergency wards in small cities and towns southwest of Beijing are overwhelmed.

source